AJMC September 8, 2023
Drug spending for products facing generic or biosimilar competition decreased during the same time period.
New drugs entering the market were associated with the majority of increases in Medicare Part B spending, and some of the remainder growth in drug spending stemmed from price growth for existing single-source drugs. In comparison, Part B drug spending decreased for existing drugs facing generic or biosimilar competition.
As a result, policies targeting price growth may not have as much impact on Part B drug spending as those targeting top-selling drugs, according to a study published in JAMA Health Forum.
“From 2008 to 2021, Part B drug spending per fee-for-service (FFS) enrollee increased 9.2% per year compared with the 2.6% increase in Part D...
Today's Sponsors
Today's Sponsor